Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 15;13:1192512. doi: 10.3389/fcimb.2023.1192512

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Kim, Jang, Lee, Ko, Lee, Cho, Lee, Song, Hyun, Kim, Hwang, Ryou, Na, Lee, Lee, Lee, Shin, Kwon, Kim and Peck

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Progression-free survival analysis in the total cohort and delta-confirmed subgroup. The 21-day probabilities for O₂ support–free survival (A) and progression free survival for severe disease (B) were evaluated in the total cohort, and the regdanvimab group showed clinical benefit for both outcomes. Significant benefits were found in the pre-delta subgroup for O₂ support–free survival (C) or progression free survival for severe disease (D), whereas those were not found in the delta-confirmed subgroup for O₂ support–free survival (E) or progression free survival for severe disease (F).